Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Epirubicin × Lymphoid × Clear all

Phase

Phase 2 10 Phase 3 3 Phase 1/2 2 Phase NA 1 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 8 Genitourinary 2 Lymphoid 1 Gastrointestinal 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 27 Vincristine 24 Dexamethasone 22 Rituximab 21 Methotrexate 21 Cytarabine 21 Mercaptopurine 16 Doxorubicin 15 Etoposide 13 Asparaginase 13 Daunorubicin 12 Prednisone 10 Prednisolone 10 Granulocyte Colony-Stimulating Factor 10 Ifosfamide 8 Idarubicin 8 fludarabine 7 pegylated granulocyte colony-stimulating factor 6 Thioguanine 6 Teniposide 6 Vindesine 5 Brentuximab Vedotin 5 ibrutinib 4 fludarabine phosphate 4 Stem Cell Transplantation 4 Gemcitabine 4 Cisplatin 4 Aprepitant 4 zanubrutinib 3 prednylidene 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02752815 2022-12-05

Reduced Chemotherapy in Low Risk DLBCL

Ruijin Hospital

Phase 4 Unknown

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡